Evidence map›Paper›PMID 39167280›Full record

ReviewCurrent allergy and asthma reports2024

Impact of Enolase in Allergic Disease.

Martha Beatriz Morales-Amparano, Maria G Teran, José Ángel Huerta-Ocampo, Luis M Teran

Abstract readReview
In one paragraph

Review in Current allergy and asthma reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. The allergenic potential of enolases: physiological and pathophysiological insights.Current opinion in allergy and clinical immunology · 2025
    Review
  4. Antimicrobial agents and chemotherapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Martha Beatriz Morales-AmparanoFood Science Department, Centro de Investigación en Alimentación y Desarrollo, A.C. (CIAD), Carretera Gustavo Enrique Astiazarán Rosas No. 46, 83304, Hermosillo, Sonora, México.
Maria G TeranImmunogenetics and Allergy Department, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosio Villegas (INER), Calzada de Tlalpan No. 4502, 14080, Ciudad de Mexico, México.
José Ángel Huerta-OcampoFood Science Department, Centro de Investigación en Alimentación y Desarrollo, A.C. (CIAD), Carretera Gustavo Enrique Astiazarán Rosas No. 46, 83304, Hermosillo, Sonora, México.
Luis M TeranImmunogenetics and Allergy Department, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosio Villegas (INER), Calzada de Tlalpan No. 4502, 14080, Ciudad de Mexico, México. teranjlm@gmail.com.

Funding

Conahcyt 332690
6 · The paper itself

Abstract

purpose of reviewThere is growing evidence that enolase is involved in allergy. This manuscript reviews the impact of enolase in allergic disease and describes several sources of this allergen including molds, plants, animals, and pollens, among others. IgE epitopes are carefully analyzed as they may account for cross-reactivity. RECENT

findingsEnolase has been previously associated to food allergy and contact dermatitis. However, other groups and we have identified recently novel enolases derived from diverse pollens in patients suffering asthma and allergic rhinitis. Exposure to outdoor enolases may cause respiratory disease. Enolase has been identified across various species and its amino acid sequence is highly conserved among different sources of this allergen. The demonstration that enolase is involved in many allergic diseases including respiratory allergies, is of clinic relevance. Thus, the development of novel molecular-based diagnostic and therapeutic strategies may pave the way for improved diagnosis and therapeutics.

Indexed as

AllergensHypersensitivityPhosphopyruvate HydrataseAnimalsCross ReactionsHumansImmunoglobulin EPollenAllergensImmunoglobulin EPhosphopyruvate HydrataseAllergyCross-reactivityEnolasesIgE-epitopes

Identifiers

PMID39167280
PMCPMC11377513

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.